Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PHIBRO ANIMAL HEALTH CORPPAHC · Entity 4671 | Director · Executive Chairman · 10% owner | August 06, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PHIBRO ANIMAL HEALTH CORP
Report date August 06, 2026 · Filed August 10, 2026
Jointly reported with BFI Co., LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 26,640 |
Reported balance
After 2026-08-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-06 · Grant · Acquired 12,103 · Balance 26,640 F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. F3: The reported securities are directly held by Jack Bendheim. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee | 56,152 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 56,152 F4: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.
F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date.
F3: The reported securities are directly held by Jack Bendheim.
F4: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 10, 2026 20:16 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | GrantClass A Common Stock | 12,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-093385 · tm2622592-3_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · Executive Chairman · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,640 F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. F3 · ownership.direct: The reported securities are directly held by Jack Bendheim. Read SEC document |
| August 04, 2026 Filed Aug 7, 2026 00:12 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | OtherClass A Common Stock | 2,303 | $36.60 | $84,287.50 |
DisclosureSEC source: 0001104659-26-092233 · tm2622506-6_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · Executive Chairman · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,537 F1 · shares: Represents shares sold in a broker assisted cashless exercise program to satisfy tax withholding obligations upon the receipt of Class A Common Stock in connection with the vesting and settlement of restricted stock units. F2 · ownership.direct: The reported securities are directly held by Jack Bendheim. Read SEC document |
| May 07, 2026 Filed May 7, 2026 23:34 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,029 | $49.19 | $99,815.03 |
DisclosureSEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 7 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 56,152 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.50. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 07, 2026 Filed May 7, 2026 23:34 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,149 | $48.31 | $55,505.20 |
DisclosureSEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 6 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 58,181 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.835. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 07, 2026 Filed May 7, 2026 23:34 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,350 | $47.59 | $64,247.58 |
DisclosureSEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 59,330 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.995. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 06, 2026 Filed May 7, 2026 23:34 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,406 | $58.13 | $81,724.73 |
DisclosureSEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 60,680 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.965 to $58.31. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 06, 2026 Filed May 7, 2026 23:34 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 5,634 | $57.18 | $322,125.08 |
DisclosureSEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 62,086 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.825 to $57.72. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 05, 2026 Filed May 7, 2026 23:34 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 776 | $56.37 | $43,739.24 |
DisclosureSEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 67,720 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.235 to $56.51. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 05, 2026 Filed May 7, 2026 23:34 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,264 | $55.73 | $349,070.80 |
DisclosureSEC source: 0001104659-26-057389 · tm2613857-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 68,496 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.225 to $56.21. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 9. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 30, 2026 Filed Apr 30, 2026 23:20 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,235 | $53.32 | $65,847.61 |
DisclosureSEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 7 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 74,760 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.22 to $53.39. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 30, 2026 Filed Apr 30, 2026 23:20 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 5,805 | $52.65 | $305,617.58 |
DisclosureSEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 6 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 75,995 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.16 to $53.09. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 23:20 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 3,038 | $53.21 | $161,645.30 |
DisclosureSEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 81,800 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.775. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 23:20 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,002 | $52.70 | $210,907.40 |
DisclosureSEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 84,838 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.97. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 23:20 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 797 | $56.69 | $45,181.61 |
DisclosureSEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 88,840 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.53 to $56.875. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 23:20 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,591 | $56.06 | $257,374.67 |
DisclosureSEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 89,637 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.51 to $56.50. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 23:20 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,652 | $55.10 | $91,018.59 |
DisclosureSEC source: 0001104659-26-053249 · tm2613153-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 94,228 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.51 to $55.40. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 9. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 23:30 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 421 | $54.56 | $22,969.00 |
DisclosureSEC source: 0001104659-26-047933 · tm2612536-1_4seq1.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 95,880 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.515 to $54.61. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 23:30 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,619 | $54.07 | $357,856.90 |
DisclosureSEC source: 0001104659-26-047933 · tm2612536-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 96,301 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.51 to $54.50. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 22, 2026 Filed Apr 23, 2026 23:30 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 7,040 | $54.29 | $382,184.70 |
DisclosureSEC source: 0001104659-26-047933 · tm2612536-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 102,920 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.73 to $54.665. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 23:30 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 5,415 | $56.17 | $304,136.72 |
DisclosureSEC source: 0001104659-26-047933 · tm2612536-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 109,960 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.91 to $56.56. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 23:30 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,625 | $55.35 | $89,943.91 |
DisclosureSEC source: 0001104659-26-047933 · tm2612536-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 115,375 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.905 to $55.88. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5, 6 and 7. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 00:25 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · derivative · entry 10 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 19,496,034 Underlying: Class A Common Stock · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F8 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 00:25 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,850 | $54.88 | $101,520.42 |
DisclosureSEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 8 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 117,000 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F10 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.80 to $54.985. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 00:25 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 5,190 | $54.56 | $283,141.49 |
DisclosureSEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 7 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 118,850 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.80 to $54.79. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 00:25 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 6 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 124,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 00:25 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 799 | $58.11 | $46,431.97 |
DisclosureSEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 24,040 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.92 to $58.22. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 00:25 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 3,618 | $57.21 | $206,985.42 |
DisclosureSEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 24,839 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.90 to $57.88. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 00:25 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,623 | $56.27 | $147,593.85 |
DisclosureSEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 28,457 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.87 to $56.73. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 14, 2026 Filed Apr 17, 2026 00:25 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 492 | $59.69 | $29,368.66 |
DisclosureSEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 31,080 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.63 to $59.83. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 14, 2026 Filed Apr 17, 2026 00:25 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,548 | $59.03 | $386,553.32 |
DisclosureSEC source: 0001104659-26-044506 · tm2611963-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 31,572 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.63 to $59.61. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5, 6, 7, 9 and 10. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 22:44 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 431 | $54.35 | $23,426.27 |
DisclosureSEC source: 0001104659-26-037978 · tm2610803-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 38,120 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.28 to $54.51. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 22:44 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,609 | $53.87 | $356,001.72 |
DisclosureSEC source: 0001104659-26-037978 · tm2610803-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 38,551 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.27 to $54.26. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 22:44 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 617 | $54.31 | $33,508.65 |
DisclosureSEC source: 0001104659-26-037978 · tm2610803-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 45,160 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.23 to $54.385. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 22:44 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,423 | $53.54 | $343,897.05 |
DisclosureSEC source: 0001104659-26-037978 · tm2610803-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 45,777 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.23 to $54.075. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5 and 6. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 280 | $57.17 | $16,007.66 |
DisclosureSEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 7 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 52,200 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.14 to $57.24. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,760 | $56.79 | $383,867.95 |
DisclosureSEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 6 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 52,480 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.12 to $57.06. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 552 | $56.86 | $31,385.84 |
DisclosureSEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 59,240 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.76 to $56.91. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,916 | $56.00 | $275,316.16 |
DisclosureSEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 59,792 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.76 to $56.745. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,572 | $55.28 | $86,903.62 |
DisclosureSEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 64,708 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.69 to $55.65. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 24, 2026 Filed Mar 27, 2026 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 517 | $53.59 | $27,705.31 |
DisclosureSEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 66,280 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.53 to $53.70. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 24, 2026 Filed Mar 27, 2026 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,523 | $52.88 | $344,917.98 |
DisclosureSEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 66,797 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.44 to $53.435. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 9. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 19, 2026 Filed Mar 19, 2026 23:58 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 124 | $53.24 | $6,601.76 |
DisclosureSEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 7 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 73,320 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 19, 2026 Filed Mar 19, 2026 23:58 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,977 | $52.79 | $262,717.91 |
DisclosureSEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 6 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 73,444 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.195 to $53.125. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 19, 2026 Filed Mar 19, 2026 23:58 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,939 | $51.78 | $100,409.37 |
DisclosureSEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 78,421 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.19 to $52.18. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 23:58 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,651 | $53.64 | $142,209.18 |
DisclosureSEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 80,360 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.365 to $53.88. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 23:58 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 3,598 | $53.03 | $190,819.21 |
DisclosureSEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 83,011 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.35 to $53.295. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 23:58 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,311 | $51.80 | $223,301.18 |
DisclosureSEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 86,609 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.29 to $52.21. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 23:58 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 5,280 | $51.66 | $272,759.52 |
DisclosureSEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 90,920 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.26 to $52.13. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 8. F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 20:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 5,280 | $48.91 | $258,244.80 |
DisclosureSEC source: 0001104659-26-028472 · tm268840-1_4seq1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 96,200 F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on December 11, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.48 to $49.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 20:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-028472 · tm268840-1_4seq1.xml · derivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner BFI Co., LLC · CIK 0001601607 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Disclosed balance after: 19,596,034 Underlying: Class A Common Stock · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.